Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug320 | Antibody-Rich Plasma from COVID-19 recovered patients Wiki | 0.71 |
| drug1325 | EUROIMMUN assay Wiki | 0.71 |
| drug2916 | Placebo Wiki | 0.06 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018352 | Coronavirus Infections NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
This is a Phase 2, multicentre, randomized, double blind, 2 arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms.
This is a two-part, Phase 2, multicentre, randomized, double blind, 2-arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms
Description: All-cause mortality
Measure: Mortality Time: From Day 1 to 6 weeksDescription: Proportion of patients with Treatment Emergent Adverse Events (TEAE) leading to study drug discontinuation
Measure: TEAE Time: From Day 1 to 6 weeksDescription: Serious adverse event (SAE) coded by System Organ Class (SOC) and Preferred Term (PT), using the Medical Dictionary for Regulatory Activities (MedDRA)
Measure: SAEs Time: From Day 1 to end of studyDescription: Change in safety laboratory tests from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided
Measure: Safety laboratory Time: From Day 1 to 6 weeksDescription: Change in sitting systolic and diastolic blood pressure from baseline to 6 weeks summarized descriptively by visit and presented as shift tables
Measure: Blood pressure Time: From Day 1 to 6 weeksDescription: time to fecal RNA virus clearance (rectal swab or stool sample) assessed by RT-qPCR in the niclosamide group, compared to the placebo group (Part 2 only)
Measure: fecal RNA virus clearance Time: From Day 1 to 6 weeksDescription: Change in body temperature from baseline to 6 weeks summarized descriptively by visit and presented as shift tables
Measure: Body temperature Time: From Day 1 to 6 weeksDescription: Change in heart rate from baseline to 6 weeks summarized descriptively by visit and presented as shift tables
Measure: Heart rate Time: From Day 1 to 6 weeksDescription: Change in SaO2 from baseline to 6 weeks summarized descriptively by visit and presented as shift tables
Measure: SaO2 Time: From Day 1 to 6 weeksDescription: Change in ECG parameters including: 1. PR interval 2. RR interval 3. QRS interval 4 QT interval 5. HR interval 6. QtcF interval. All intervals summarized descriptively by visit from baseline to 6 weeks
Measure: ECG Time: From Day 1 to 6 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports